**Supplemental Table 1. The changes of SHAPS and MADRS anhedonia factor scores with treatment of vortioxetine in patients with SHAPS score > 3 at baseline.**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variables | **Baseline (n=67)** |  | **Week 2 (n=66)** | | | |  | **Week 8 (n=58)** | | | |
| M±SD |  | M±SD | *Δbaseline (95% CI)* | *z* | *p* |  | M±SD | *Δbaseline (95% CI)* | *z* | *p* |
| **SHAPS score** | 8.1±2.7 |  | 6.7±4.3 | -1.4 (-2.3, -0.5) | -3.04 | 0.002*\** |  | 4.3±4.1 | -3.8 (-4.8, -2.9) | -8.03 | <0.0001*\** |
| **MADRS anhedonia factor** | 19.0±3.5 |  | 15.2±5.3 | -3.9 (-5.1, -2.6) | -5.98 | <0.0001*\** |  | 12.3±5.9 | -6.9 (-8.2, -5.5) | -10.10 | <0.0001*\** |

\* indicates significant differences from baseline.